A comprehensive view of sanofi sa. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Sanofi partners with TrialSpark to pursue acquisition/in-licensing and development of clinical-stage Phase 2, Phase 3 drug candidates in areas of high unmet patient need; firms are jointly targeting six transactions over the next three years
Published: October 04, 2022 by PR Newswire
FDA approves Regeneron and Sanofi’s injectable Dupixent dupilumab to treat adult patients with prurigo nodularis, making it the first and only medicine specifically indicated to treat the disease; 75,000 adults in the US have prurigo nodularis
Published: September 29, 2022 by PR Newswire
US Solicitor General suggests Supreme Court turn down Amgen’s request to hear PCSK9 patent case with Sanofi and Regenron; appeals court ruling called Amgen’s claims invalid because it would take ‘undue experimentation’ to enable their full scope
Published: September 26, 2022 by FiercePharma
FDA approves three Sanofi quadrivalent flu vaccines for 2022-2023 influenza season; CDC estimates that since 2010, 70% to 85% of seasonal flu-related deaths occur in people 65 years old and older
Published: September 23, 2022 by Drug Store News
Sanofi Mexico CEO announces company is ready to produce first 100% Mexican influenza vaccine; plant currently making validation batches in public-private partnership with Mexican government
Published: September 22, 2022 by CE Noticias Financieras

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count